Oruka Therapeutics
ORKA
31 hedge funds and large institutions have $49.4M invested in Oruka Therapeutics in 2024 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 5 closing their positions.
290% more capital invested
Capital invested by funds: $12.7M → $49.4M (+$36.7M)
288% more call options, than puts
Call options by funds: $163K | Put options by funds: $42K
180% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 5
41% more funds holding
Funds holding: 22 → 31 (+9)
3.28% more ownership
Funds ownership: 4.14% → 7.42% (+3.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$4.65M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$4.59M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.99M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$3.32M |
| 5 |
VA
VR Adviser
New York
|
+$2.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSL
Western Standard LLC
Los Angeles,
California
|
-$2.48M |
| 2 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$1.24M |
| 3 |
HF
HRT Financial
New York
|
-$22K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$9.05K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$358 |
ORKA Hedge Fund Activity: Q2 2024 in Review
31 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q2 2024, worth a combined $49.4M — up 290% from $12.7M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ORKA positions and 5 closed out — a net gain of 9 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was RTW Investments, opening a new position worth an estimated $4.65M. The largest seller was Western Standard LLC, exiting entirely with an estimated $2.48M sold.
- 31 institutional investors held Oruka Therapeutics (ORKA) as of Q2 2024, up from 22 in Q1 2024.
- Funds reported $49.4M of Oruka Therapeutics stock for Q2 2024, up 290% quarter-over-quarter.
- 14 funds opened new Oruka Therapeutics positions in Q2 2024 and 5 closed out, a net change of +9 holders.
- The largest Oruka Therapeutics buyer in Q2 2024 was RTW Investments, an estimated $4.65M added.
- The largest Oruka Therapeutics seller in Q2 2024 was Western Standard LLC, an estimated $2.48M sold.
Based on aggregated 13F filings for Q2 2024.